Guidelines for identification and treatment of individuals with attention deficit/hyperactivity disorder and associated fetal alcohol spectrum disorders based upon expert consensus

Susan Young; Michael Absoud; Carolyn Blackburn; Polly Branney; Bill Colley; Emad Farrag; Susan Fleisher; Ges Gregory; Gisli H. Gudjonsson; Keira Kim; Kieran D. O'Malley; Moira Plant; Alina Rodriguez; Susan Ozer; Inyang Takon; Emma Woodhouse; Raja Mukherjee

doi:10.1186/s12888-016-1027-y

Guidelines for identification and treatment of individuals with attention deficit/hyperactivity disorder and associated fetal alcohol spectrum disorders based upon expert consensus

Susan Young^*
, Michael Absoud
, Carolyn Blackburn
, Polly Branney
, Bill Colley
, Emad Farrag
, Susan Fleisher
, Ges Gregory
, Gisli H. Gudjonsson
, Keira Kim
, Kieran D. O'Malley
, Moira Plant
, Alina Rodriguez
, Susan Ozer
, Inyang Takon
, Emma Woodhouse
, Raja Mukherjee

^*Corresponding author for this work

Imperial College London
West London NHS Trust
Kings Health Partners Academic Health Science Centre
Headington
CLC Consultancy
Sussex Partnership NHS Foundation Trust
National Organisation for Foetal Alcohol Syndrome-UK (NOFAS-UK)
Cambridge and Peterborough Foundation Trust
King's College London
Contracted Medical Writer
Slievemore Clinic
Royal Society of Medicine
University of the West of England
Curtin University
Sweden University
East and North Hertfordshire NHS Trust
University of Ibadan
Surrey and Borders Partnership NHS Foundation Trust

Research output: Contribution to journal › Article › peer-review

33 Citations (SciVal)

Original language	English
Article number	324
Journal	BMC Psychiatry
Volume	16
Issue number	1
DOIs	https://doi.org/10.1186/s12888-016-1027-y
Publication status	Published (VoR) - 22 Sept 2016

Funding

SY has received honoraria for consultancy, sponsorship for attendance at scientific meetings, educational talks and/or research awards from Janssen, Lilly, Novartis, HB Pharma, Flynn Pharma and/or Shire. GHG has received consultancy fees, speaker fees and/or travel honoraria from Lilly, Janssen and Shire. RM has received speaker fees from Shire, Flynn Pharma, and Lilly. MA has received honoraria for consultancy and/or research awards from Neurim Pharmaceuticals, Novartis, MS Society, Action Medical Research Charities, Shirley Foundation and NIHR. CB has received honoraria for consultancy, sponsorship for attendance at scientific meetings, educational talks and/or research awards from the European Association for Persons with Disabilities, Fosterline England, Winston Churchill Memorial Trust, Positive Path International and Babcock International, The Department of Education, Worcestershire Local Authority, Specialist Schools and Academies Trust and a number of English primary and secondary schools. KO’M has received royalties for authorship of two books on FASD. SO has received honoraria for consultancy and/or educational talks from Flynn Pharma and Shire. MP has received honoraria for educational talks and/or research awards from the World Health Organization, the European Union, the Welcome Trust, the beverage alcohol industry and Shire. IT has received honoraria for consultancy, sponsorship for attendance at scientific meetings and/or educational talks from Shire and Flynn Pharma. The remaining authors have no disclosures. The meeting was funded by the UK ADHD Partnership (UKAP). Aside from KK, none of the authors received funds for their involvement in developing this consensus.

Keywords

Attention deficit/hyperactivity disorder (ADHD)
Co-morbid or associated FASD
Consensus
Fetal alcohol spectrum disorders (FASD)
Interventions
Treatment guidelines

Access to Document

10.1186/s12888-016-1027-y

Cite this

Young, S., Absoud, M., Blackburn, C., Branney, P., Colley, B., Farrag, E., Fleisher, S., Gregory, G., Gudjonsson, G. H., Kim, K., O'Malley, K. D., Plant, M., Rodriguez, A., Ozer, S., Takon, I., Woodhouse, E., & Mukherjee, R. (2016). Guidelines for identification and treatment of individuals with attention deficit/hyperactivity disorder and associated fetal alcohol spectrum disorders based upon expert consensus. BMC Psychiatry, 16(1), Article 324. https://doi.org/10.1186/s12888-016-1027-y

@article{9c0b1fc703364abfb4be853d721310ad,

title = "Guidelines for identification and treatment of individuals with attention deficit/hyperactivity disorder and associated fetal alcohol spectrum disorders based upon expert consensus",

keywords = "Attention deficit/hyperactivity disorder (ADHD), Co-morbid or associated FASD, Consensus, Fetal alcohol spectrum disorders (FASD), Interventions, Treatment guidelines",

author = "Susan Young and Michael Absoud and Carolyn Blackburn and Polly Branney and Bill Colley and Emad Farrag and Susan Fleisher and Ges Gregory and Gudjonsson, \{Gisli H.\} and Keira Kim and O'Malley, \{Kieran D.\} and Moira Plant and Alina Rodriguez and Susan Ozer and Inyang Takon and Emma Woodhouse and Raja Mukherjee",

note = "Funding Information: SY has received honoraria for consultancy, sponsorship for attendance at scientific meetings, educational talks and/or research awards from Janssen, Lilly, Novartis, HB Pharma, Flynn Pharma and/or Shire. GHG has received consultancy fees, speaker fees and/or travel honoraria from Lilly, Janssen and Shire. RM has received speaker fees from Shire, Flynn Pharma, and Lilly. MA has received honoraria for consultancy and/or research awards from Neurim Pharmaceuticals, Novartis, MS Society, Action Medical Research Charities, Shirley Foundation and NIHR. CB has received honoraria for consultancy, sponsorship for attendance at scientific meetings, educational talks and/or research awards from the European Association for Persons with Disabilities, Fosterline England, Winston Churchill Memorial Trust, Positive Path International and Babcock International, The Department of Education, Worcestershire Local Authority, Specialist Schools and Academies Trust and a number of English primary and secondary schools. KO{\textquoteright}M has received royalties for authorship of two books on FASD. SO has received honoraria for consultancy and/or educational talks from Flynn Pharma and Shire. MP has received honoraria for educational talks and/or research awards from the World Health Organization, the European Union, the Welcome Trust, the beverage alcohol industry and Shire. IT has received honoraria for consultancy, sponsorship for attendance at scientific meetings and/or educational talks from Shire and Flynn Pharma. The remaining authors have no disclosures. The meeting was funded by the UK ADHD Partnership (UKAP). Aside from KK, none of the authors received funds for their involvement in developing this consensus. Publisher Copyright: {\textcopyright} 2016 The Author(s).",

year = "2016",

month = sep,

day = "22",

doi = "10.1186/s12888-016-1027-y",

language = "English",

volume = "16",

journal = "BMC Psychiatry",

issn = "1471-244X",

publisher = "BioMed Central",

number = "1",

}

Young, S, Absoud, M, Blackburn, C, Branney, P, Colley, B, Farrag, E, Fleisher, S, Gregory, G, Gudjonsson, GH, Kim, K, O'Malley, KD, Plant, M, Rodriguez, A, Ozer, S, Takon, I, Woodhouse, E & Mukherjee, R 2016, 'Guidelines for identification and treatment of individuals with attention deficit/hyperactivity disorder and associated fetal alcohol spectrum disorders based upon expert consensus', BMC Psychiatry, vol. 16, no. 1, 324. https://doi.org/10.1186/s12888-016-1027-y

TY - JOUR

T1 - Guidelines for identification and treatment of individuals with attention deficit/hyperactivity disorder and associated fetal alcohol spectrum disorders based upon expert consensus

AU - Young, Susan

AU - Absoud, Michael

AU - Blackburn, Carolyn

AU - Branney, Polly

AU - Colley, Bill

AU - Farrag, Emad

AU - Fleisher, Susan

AU - Gregory, Ges

AU - Gudjonsson, Gisli H.

AU - Kim, Keira

AU - O'Malley, Kieran D.

AU - Plant, Moira

AU - Rodriguez, Alina

AU - Ozer, Susan

AU - Takon, Inyang

AU - Woodhouse, Emma

AU - Mukherjee, Raja

N1 - Funding Information: SY has received honoraria for consultancy, sponsorship for attendance at scientific meetings, educational talks and/or research awards from Janssen, Lilly, Novartis, HB Pharma, Flynn Pharma and/or Shire. GHG has received consultancy fees, speaker fees and/or travel honoraria from Lilly, Janssen and Shire. RM has received speaker fees from Shire, Flynn Pharma, and Lilly. MA has received honoraria for consultancy and/or research awards from Neurim Pharmaceuticals, Novartis, MS Society, Action Medical Research Charities, Shirley Foundation and NIHR. CB has received honoraria for consultancy, sponsorship for attendance at scientific meetings, educational talks and/or research awards from the European Association for Persons with Disabilities, Fosterline England, Winston Churchill Memorial Trust, Positive Path International and Babcock International, The Department of Education, Worcestershire Local Authority, Specialist Schools and Academies Trust and a number of English primary and secondary schools. KO’M has received royalties for authorship of two books on FASD. SO has received honoraria for consultancy and/or educational talks from Flynn Pharma and Shire. MP has received honoraria for educational talks and/or research awards from the World Health Organization, the European Union, the Welcome Trust, the beverage alcohol industry and Shire. IT has received honoraria for consultancy, sponsorship for attendance at scientific meetings and/or educational talks from Shire and Flynn Pharma. The remaining authors have no disclosures. The meeting was funded by the UK ADHD Partnership (UKAP). Aside from KK, none of the authors received funds for their involvement in developing this consensus. Publisher Copyright: © 2016 The Author(s).

PY - 2016/9/22

Y1 - 2016/9/22

KW - Attention deficit/hyperactivity disorder (ADHD)

KW - Co-morbid or associated FASD

KW - Consensus

KW - Fetal alcohol spectrum disorders (FASD)

KW - Interventions

KW - Treatment guidelines

UR - https://www.scopus.com/pages/publications/84988499041

UR - https://www.scopus.com/pages/publications/84988499041#tab=citedBy

U2 - 10.1186/s12888-016-1027-y

DO - 10.1186/s12888-016-1027-y

M3 - Article

AN - SCOPUS:84988499041

SN - 1471-244X

VL - 16

JO - BMC Psychiatry

JF - BMC Psychiatry

IS - 1

M1 - 324

ER -

Guidelines for identification and treatment of individuals with attention deficit/hyperactivity disorder and associated fetal alcohol spectrum disorders based upon expert consensus

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this